Complement Factor H and Complement Factor H-Related Protein 5 Mutations Associated with Atypical Hemolytic Uremic Syndrome in a Systemic Lupus Erythematosus Patient: Efficacy of Eculizumab

Ersan, SİBEL; Erkul, Bengu; Avcioglu Yilmaz, Banu; GÜLLE, SEMİH; Yilmaz, Zevcet

doi:10.5262/tndt.2018.2652

Complement Factor H and Complement Factor H-Related Protein 5 Mutations Associated with Atypical Hemolytic Uremic Syndrome in a Systemic Lupus Erythematosus Patient: Efficacy of Eculizumab

Ersan S., Erkul B., Avcioglu Yilmaz B., GÜLLE S., Yilmaz Z.

TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, cilt.27, sa.3, ss.308-312, 2018 (ESCI, Scopus, TRDizin)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 27 Sayı: 3
Basım Tarihi: 2018
Doi Numarası: 10.5262/tndt.2018.2652
Dergi Adı: TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.308-312
Anahtar Kelimeler: SLE, aHUS, Eculizumab
Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Atypical hemolytic uremic syndrome (aHUS) is a disorder characterized by a propensity to thrombotic microangiopathy (TMA) due to defective regulation of the alternative complement pathway. Mutations in genes encoding complement factor H (CFH) and complement factor H-related proteins (CH IR) can be related with aHUS and identified in patients with rheumatologic diseases.